Literature DB >> 6226743

Comparison of binding characteristics of factors B and H to C3b on normal and paroxysmal nocturnal hemoglobinuria erythrocytes.

C J Parker, P J Baker, W F Rosse.   

Abstract

To determine if aberrant interactions of the endogenous control proteins with cell-bound C3b contribute to the greater fixation of C3b to paroxysmal nocturnal hemoglobinuria (PNH) erythrocytes when whole serum complement is activated, we compared the characteristics of binding of factors B and H to normal and PNH red cells bearing C3b (EC3b). Factor B binding is homogeneous, there is 1:1 stoichiometry, and the affinity constant at equilibrium for factor B binding is the same for normal and PNH EC3b. In contrast, analysis by Scatchard's method of factor H binding results in a curvilinear plot, the deviation from linearity being exaggerated for the PNH EC3b. The heterogeneity of binding of factor H appears to be a consequence of the nonrandom distribution of C3b about the alternative pathway convertase site. This nonrandom distribution does not induce negative cooperativity but rather effects a biophysical milieu which enhances factor H binding. The greater heterogeneity of binding of factor H to PNH E bearing nonrandomly distributed C3b appears to be due to the presence of a greater proportion of lower affinity binding sites on the PNH EC3b. However, it appears unlikely that this greater heterogeneity of factor H binding contributes to the enhanced fixation of C3b to PNH erythrocytes.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6226743

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

1.  Effect of complement-protein-C3b density on the binding of complement factor H to surface-bound C3b.

Authors:  V Koistinen
Journal:  Biochem J       Date:  1991-11-15       Impact factor: 3.857

2.  Isolation and characterization of a membrane protein from normal human erythrocytes that inhibits reactive lysis of the erythrocytes of paroxysmal nocturnal hemoglobinuria.

Authors:  M H Holguin; L R Fredrick; N J Bernshaw; L A Wilcox; C J Parker
Journal:  J Clin Invest       Date:  1989-07       Impact factor: 14.808

3.  Abnormality of glycophorin-alpha on paroxysmal nocturnal hemoglobinuria erythrocytes.

Authors:  C J Parker; C M Soldato; W F Rosse
Journal:  J Clin Invest       Date:  1984-04       Impact factor: 14.808

4.  Amelioration of lytic abnormalities of paroxysmal nocturnal hemoglobinuria with decay-accelerating factor.

Authors:  M E Medof; T Kinoshita; R Silber; V Nussenzweig
Journal:  Proc Natl Acad Sci U S A       Date:  1985-05       Impact factor: 11.205

5.  Identification of three physically and functionally distinct binding sites for C3b in human complement factor H by deletion mutagenesis.

Authors:  A K Sharma; M K Pangburn
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-01       Impact factor: 11.205

6.  Increased efficiency of binding of nascent C3b to the erythrocytes of chronic cold agglutinin disease.

Authors:  C J Parker; C M Soldato; M J Telen
Journal:  J Clin Invest       Date:  1984-09       Impact factor: 14.808

7.  Characterization of the complement sensitivity of paroxysmal nocturnal hemoglobinuria erythrocytes.

Authors:  C J Parker; T Wiedmer; P J Sims; W F Rosse
Journal:  J Clin Invest       Date:  1985-06       Impact factor: 14.808

8.  Decay-accelerating factor protects human tumor cells from complement-mediated cytotoxicity in vitro.

Authors:  N K Cheung; E I Walter; W H Smith-Mensah; W D Ratnoff; M L Tykocinski; M E Medof
Journal:  J Clin Invest       Date:  1988-04       Impact factor: 14.808

9.  Relationship between decay accelerating factor deficiency, diminished acetylcholinesterase activity, and defective terminal complement pathway restriction in paroxysmal nocturnal hemoglobinuria erythrocytes.

Authors:  M E Medof; A Gottlieb; T Kinoshita; S Hall; R Silber; V Nussenzweig; W F Rosse
Journal:  J Clin Invest       Date:  1987-07       Impact factor: 14.808

10.  Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes.

Authors:  M E Medof; T Kinoshita; V Nussenzweig
Journal:  J Exp Med       Date:  1984-11-01       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.